» Articles » PMID: 26171937

Impact of P16 Status on Pro- and Anti-angiogenesis Factors in Head and Neck Cancers

Overview
Journal Br J Cancer
Specialty Oncology
Date 2015 Jul 15
PMID 26171937
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Head and neck cancers (HNC) are aggressive tumours. Overexpression of p16 in HNC correlates with human papilloma virus (HPV)-associated HNC that carry a better prognosis than HPV-negative tumours. Angiogenesis is an important factor in tumour progression. Our aim was to dissect the impact of p16 expression on angiogenesis factors in HNC.

Methods: Eighteen newly diagnosed HNC patients and controls were analysed. Eleven pro- and anti-angiogenesis factors were quantified using multiplex ELISA in HNC patients and controls. Angiogenesis factors were analysed in tumour tissue using immunohistochemistry.

Results: Circulating levels of endostatin (anti-angiogenesis factor) were higher in the HNC group compared with healthy donors. Interestingly, the pro-angiogenesis factors angiopoietin-1 and vascular endothelial growth factor (VEGF) were significantly higher in patients with p16-negative compared with p16-positive HNC. Moreover, the major source of VEGF in p16-positive HNC tissue was tumour stromal cells. In contrast, both tumour cells and stromal cells expressed VEGF in p16-negative tissue.

Conclusions: We show that p16-negative tumours associate with increased circulating levels of pro-angiogenic VEGF and angiopoietin-1. Tissue expression of VEGF differs between p16-positive and p16-negative tumours. These findings may explain differences in the biological behaviour of p16-positive and p16-negative HNC. Better understanding of mechanisms by which the p16 status influences tumour angiogenesis may guide the development of targeted therapies.

Citing Articles

Context-dependent effects of CDKN2A and other 9p21 gene losses during the evolution of esophageal cancer.

Ganguli P, Basanta C, Acha-Sagredo A, Misetic H, Armero M, Mendez A Nat Cancer. 2025; 6(1):158-174.

PMID: 39753721 PMC: 11779637. DOI: 10.1038/s43018-024-00876-0.


Functional analysis of fibroblasts and macrophages in head and neck paragangliomas.

Baruah P, Marshall J, Nefla M, Pucino V, Adams H, Turner J Front Endocrinol (Lausanne). 2024; 15:1397839.

PMID: 39619326 PMC: 11604431. DOI: 10.3389/fendo.2024.1397839.


Aspartate-β-hydroxylase and hypoxia marker expression in head and neck carcinomas: implications for HPV-associated tumors.

Smahelova J, Pokryvkova B, Stovickova E, Grega M, Vencalek O, Smahel M Infect Agent Cancer. 2024; 19(1):26.

PMID: 38858774 PMC: 11163809. DOI: 10.1186/s13027-024-00588-1.


Tumor hypoxia and role of hypoxia-inducible factor in oral cancer.

Singh P, Rajput M, Pandey M World J Surg Oncol. 2024; 22(1):18.

PMID: 38200568 PMC: 10782715. DOI: 10.1186/s12957-023-03284-3.


Histological and immunohistochemical prognostic factors of primary angiosarcoma.

Ichiki T, Yamada Y, Ito T, Nakahara T, Nakashima Y, Nakamura M Virchows Arch. 2023; 483(1):59-69.

PMID: 37261506 DOI: 10.1007/s00428-023-03572-z.


References
1.
Peng L, Bu Z, Zhou Y, Ye X, Liu J, Zhao Q . Hemorrhagic events in cancer patients treated with aflibercept: a meta-analysis. Tumour Biol. 2014; 35(9):9419-27. DOI: 10.1007/s13277-014-2189-1. View

2.
Sun R, Wu J, Chen Y, Lu M, Zhang S, Lu D . Down regulation of Thrombospondin2 predicts poor prognosis in patients with gastric cancer. Mol Cancer. 2014; 13:225. PMC: 4189190. DOI: 10.1186/1476-4598-13-225. View

3.
Naumnik W, Ossolinska M, Plonska I, Chyczewska E, Niklinski J . Circulating Thrombospondin-2 and FGF-2 in Patients with Advanced Non-small Cell Lung Cancer: Correlation with Survival. Adv Exp Med Biol. 2014; 833:9-14. DOI: 10.1007/5584_2014_78. View

4.
McMahon G . VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000; 5 Suppl 1:3-10. DOI: 10.1634/theoncologist.5-suppl_1-3. View

5.
Thomas J, Arzoomanian R, Alberti D, Marnocha R, Lee F, Friedl A . Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol. 2003; 21(2):223-31. DOI: 10.1200/JCO.2003.12.120. View